Defining Platinum Sensitivity in SCLC

Author(s):

Panelists discuss how the definition of platinum sensitivity in extensive-stage small cell lung cancer may still rely on the 90-day criterion, while also exploring other factors contributing to treatment resistance, alongside an examination of tarlatamab’'s unique mechanism as a bispecific T-cell engager and its potential as a subsequent therapy after platinum-based chemotherapy.

EP: 1.Current Landscape of First-Line Treatment for Limited-Stage SCLC: Diagnostic Workup & Multidisciplinary Approaches

EP: 2.Surgical and Radiotherapy Choices in Limited-Stage SCLC

EP: 3.Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications

EP: 4.Immunotherapy in Limited-Stage SCLC

Now Viewing

EP: 5.Defining Platinum Sensitivity in SCLC

EP: 6.Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment

EP: 7.Adverse Event Management: CRS and ICANS with Tarlatamab

EP: 8.Tarlatamab in Combination Therapy: Future Potential for SCLC

EP: 9.Ifinatamab Deruxtecan and B7-H3 in SCLC

EP: 10.Comparing Treatment Schedules: Ifinatamab Deruxtecan vs Amrubicin, Topotecan, and Lurbinectedin in SCLC

EP: 11.Insights from ARTEMIS-001

EP: 12.Targeted Therapies and Biomarkers for SCLC: What’s Next on the Horizon

Video content above is prompted by the following:

1. Dr Sen: At the community practice level, does 90 days continue to define platinum sensitivity status among patients with extensive-stage small cell lung cancer (SCLC)?

What other factors contribute to the definition of treatment resistance in this patient subgroup?

2. Dr Iams: Please briefly discuss the unique mechanism of action of tarlatamab, a bispecific T-cell engager, and its treatment potential as subsequent therapy for SCLC that has progressed after platinum-based chemotherapy.